Atheromatous showers, periprocedural myocardial infarction, and fatality

American Heart Journal

Volumn 145, Issue 6, 2003, Pages 933-935

  Yen, Michael H ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CHOLESTEROL; CREATINE KINASE; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIN; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIENO[2,3 B]PYRIDINE DERIVATIVE; TROPONIN; BIOLOGICAL MARKER;

ATHERECTOMY; ATHEROMA; CORONARY RISK; EDITORIAL; EMBOLISM; FATALITY; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; BLOOD; MORTALITY; NOTE; REFERENCE VALUE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CREATINE KINASE; HUMANS; PROGNOSIS; REFERENCE VALUES;

EID: 0037944256     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00096-6     Document Type: Editorial

References (16)

1. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-90.
2. Kotani J, Nanto S, Mintz GS, et al. Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation 2002;106:1672-7.
3. Bonderman D, Teml A, Jakowitsch J, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002;99:2794-800.
4. Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. Circ Res 2001;89:1-2.
5. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104:992-7.
6. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-51.
7. Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol 2000;85:1077-82.
8. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
9. Kini A, Kini S, Marmur JD, et al. Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. Catheter Cardiovasc Interv 1999;48:123-9.
10. Abdelmeguid AE, Topol EJ. The myth of the myocardial "infarctlet" during percutaneous coronary revascularization procedures. Circulation 1996;94:3369-75.
11. Elliott JM, Berdan LG, Holmes DR, et al. One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVE-AT I). Circulation 1995;91:2158-66.
12. Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002;106:1205-10.
13. Ghazzal Z, Ashfaq S, Morris DC, et al. Prognostic implication of creatine kinase release after elective precutaneous coronary intervention in the pre-IIb/IIIa antagonist era. Am Heart J 2003;145:1006-12.
14. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002;113:1-6.
15. Abdelmeguid AE, Topol EJ, Whitlow PL, et al. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-36.
16. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999;354:2019-24.